Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 33 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|---|
Oct. 31, 2023 |
Jun. 30, 2021 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2022 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
| Current portion of deferred revenue | $ 0 | $ 0 | $ 6,659 | $ 0 | |||||
| Lilly Agreement | |||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
| Agreement description | In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events. Through June 30, 2026, the Company has recognized a total of $50.0 million of milestone related revenue, including $25.0 million during the six months ended June 30, 2026 | ||||||||
| Collaboration agreement upfront payment received | $ 200,000 | ||||||||
| Collaboration agreement milestone payments received | 50,000 | ||||||||
| Collaboration agreement performance obligation revenue recognized | $ 0 | 25,000 | $ 0 | 50,000 | |||||
| Deferred revenue liability | 0 | 0 | 0 | ||||||
| Lilly Agreement | Maximum | |||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
| Additional proceeds from potential future development-stage payments | $ 350,000 | ||||||||
| Apellis Pharmaceuticals, Inc | |||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
| Agreement description | In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company conducted preclinical research on six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis had an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and collectively, the Opt-In Rights, and would assume responsibility for subsequent development. In 2025, Apellis notified the Company of its decision to opt-in to one of the six base editing programs. As a result of Apellis' decision to opt-in to the program, the Company received a cash opt-in fee of $3.8 million which was recognized as revenue during the year ended December 31, 2025. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis. | ||||||||
| Collaboration agreement term of contract | 5 years | ||||||||
| Collaboration agreement performance obligation revenue period for recognition | 5 years | ||||||||
| Collaboration agreement aggregate transaction price | $ 75,000 | ||||||||
| Collaboration agreement performance obligation revenue recognized | 500 | $ 6,300 | 7,200 | $ 11,700 | |||||
| Upfront fee receivable upon signing contract | $ 50,000 | ||||||||
| Collaboration agreement first anniversary amount receivable | $ 25,000 | ||||||||
| Current portion of deferred revenue | $ 0 | $ 0 | $ 0 | ||||||
| opt-in fee | Apellis Pharmaceuticals, Inc | |||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
| Collaboration agreement performance obligation revenue recognized | $ 3,800 | ||||||||